The evolving place of incretin-based therapies in type 2 diabetes by Gallwitz, Baptist
REVIEW
The evolving place of incretin-based therapies
in type 2 diabetes
Baptist Gallwitz
Received: 6 September 2009 /Revised: 9 November 2009 /Accepted: 25 November 2009 /Published online: 4 February 2010
# IPNA 2010
Abstract Treatment options for type 2 diabetes based on
the action of the incretin hormone glucagon-like peptide-1
(GLP-1) were first introduced in 2005. These comprise the
injectable GLP-1 receptor agonists solely acting on the
GLP-1 receptor on the one hand and orally active
dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising
endogenous GLP-1 and other hormone levels by inhibiting
the degrading enzyme DPP-4. In adult medicine, both
treatment options are attractive and more commonly used
because of their action and safety profile. The incretin-
based therapies stimulate insulin secretion and inhibit
glucagon secretion in a glucose-dependent manner and
carry no intrinsic risk of hypoglycaemia. GLP-1 receptor
agonists allow weight loss, whereas DPP-4 inhibitors are
weight neutral. This review gives an overview of the
mechanism of action and the substances and clinical data
available.
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Introduction
Type 2 diabetes is a disease that is increasing tremendously
in prevalence worldwide, and is expected to more than
double within the next 20 years and to affect 440 million
people by 2030 [1]. Formerly mostly found in adults and
the elderly, the prevalence of type 2 diabetes is also
increasing in children and adolescents [2]. Effective and
patient-orientated treatment is still a major task, since a
large percentage of patients do not reach the therapeutic
goal of a near normal HbA1c value as one criterion for an
acceptable glycaemic control. Along with this dissatisfac-
tory therapeutic effect, other important treatment goals,
such as body weight reduction or the prevention of
hypoglycaemic episodes, are not accomplished. Further-
more, type 2 diabetic patients have a significantly elevated
cardiovascular mortality risk, which can be lowered by
improved metabolic control [3, 4]. The established thera-
pies are not able to halt the disease progression, which is
caused by the continuous loss of function of the insulin-
secreting beta cells in the islets of Langerhans. This loss of
function is characterised by an increasing defect in the
insulin response to glucose as well as a loss of beta cell
mass over time. Furthermore, many established therapies
are associated with an elevated incidence of hypoglycaemic
events (sulphonylureas, glinides and insulin) or with an
unwanted increase in body weight caused by the antidia-
betic medications (sulphonylureas, glinides, glitazones and
insulin) [5].
In the past decade, the pharmacological actions of the
incretin hormone glucagon-like peptide-1 (GLP-1) were
utilised to develop two novel substance classes for type 2
diabetes therapy: the GLP-1 receptor agonists (or “GLP-1
mimetics”) and the dipeptidyl-peptidase-IVinhibitors (DPP-4
inhibitors or “GLP-1 enhancers”)[ 6]. The incretin
hormones GLP-1 and GIP (gastric inhibitory polypeptide,
later often also referred to as glucose insulinotropic
polypeptide) are secreted postprandially from the endo-
crine L- and K-cells in the intestinal mucosa respectively.
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components (“taste receptors”) may additionally contrib-
ute to incretin secretion after a meal [7]. These hormones
are responsible for approximately 60% of the insulin
secretion following a meal and for the so-called incretin
effect. The incretin effect describes the phenomenon that
oral glucose leads to a greater insulin response than an
isoglycaemic intravenous glucose load [8, 9]. In patients
with type 2 diabetes, the incretin effect is diminished. One
important reason for this loss is that GIP does not act as an
insulinotropic hormone under chronic hyperglycaemia in type
2 diabetes. GLP-1 on the other hand is still able to stimulate
insulin secretion under hyperglycaemia in type 2 diabetes
[10]. Conversely, hyperglycaemia acutely reduces the post-
prandial levels of GIP and GLP-1, possibly through a
deceleration of gastric emptying. Therefore, the reduced
incretin levels in some patients with type 2 diabetes could be
a consequence rather than a cause of type 2 diabetes [11].
Increasing GLP-1 plasma concentrations to pharma-
cological levels by exogenous GLP-1 application leads
to a normalisation of the incretin effect with an
adequate insulin response under hyperglycaemic con-
ditions [12].
Physiological actions of GLP-1
GLP-1 is a product of the glucagon gene and is post-
translationally cleaved from preproglucagon in the neuro-
endocrine L-cells of the intestinal mucosa and in the central
nervous system. It binds to highly specific GLP-1 receptors
that belong to the G-protein coupled receptors [6]. GLP-1
shows numerous actions in different tissues and a broad
therapeutic potential (see Fig. 1 for details).
GLP-1 stimulates insulin secretion of the beta cells and
additionally inhibits glucagon secretion from the alpha
cells. Both actions occur in a glucose-dependent manner
and lead to a normalisation of postprandial and fasting
hyperglycaemia. GLP-1 furthermore slows gastric empty-
ing. This effect also contributes to a normalisation of
postprandial hyperglycaemia (see below). Under hypogly-
caemic conditions the counter-regulation by glucagon is not
affected and insulin secretion is not stimulated. GLP-1 is
therefore not able to elicit hypoglycaemia by itself [6].
Animal studies in rodents and studies in isolated
human islets showed beneficial long-term actions of
GLP-1: insulin synthesis is stimulated by GLP-1 and
beta cell mass is increased [6, 13, 14]. Whether these
Fig. 1 Multiple physiological
effects of GLP-1 (adapted with
permission from [6, 104])
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with a positive effect on halting disease progression is not
known, since long-term study data are still not available
and beta cell mass cannot yet be quantified in humans in a
clinical setting.
GLP-1 binds to its receptor on hypothalamic neurons
and stimulates satiety. In the gastrointestinal tract, GLP-1
has a direct effect on motility and slows gastric
emptying. These two effects explain that long-term
treatment with GLP-1 receptor agonists lead to weight
loss in the long run [6].
Furthermore, pharmacological application of GLP-1
receptor agonists lead to an improvement in cardiovascular
parameters (reduction of systolic blood pressure, beneficial
effects on myocardial ischaemia in animal models, positive
effects on left ventricular function in heart failure) [15–17].
GLP-1 is degraded rapidly by the ubiquitous enzyme
dipeptidyl-peptidase IV (DPP-4). An animal study in
rodents even showed that DPP-4 expression in the
intestine and kidneys increased with high-fat feeding
and type 2 diabetes [18]. Intravenously administered
GLP-1 has a biological half-time of approximately only
1–2m i n[ 6]. Also, subcutaneous injections of GLP-1 do
not lead to a sufficiently high and long-lasting elevation of
GLP-1 concentrations to use native GLP-1 as a practical
therapeutic agent. An adenoviral vectored gene therapeutic
option transfecting the GLP-1 gene into hepatozytes of a
diabetic rat strain showed positive effects in one study, but
because of the present difficulties and safety concerns
using these methods in humans, this theoretical option has
not been followed up so far [19]. In order to utilise GLP-1
action for type 2 diabetes therapy, two options are
presently available [6]:
1. GLP-1-receptor agonists (or GLP-1 mimetics) as
injectable compounds
2. Dipeptidyl-peptidase-IV (DPP-4) inhibitors (or incretin
enhancers) as orally active substances
The following paragraphs deal with the approved
compounds.
GLP-1 receptor-agonists, exenatide and liraglutide
Exenatide (Byetta®, Eli Lilly Pharmaceuticals) was the first
GLP-1 receptor agonist to be approved for the treatment of
type 2 diabetes in combination with metformin and/or a
sulphonylurea in patients failing to reach the therapeutic
goals with this oral medication [20]. Exenatide is the
synthetic form of exendin-4, a peptide first discovered in
the saliva of the gila monster (heloderma suspectum) in
1992. It has a 53% amino acid sequence homology to
human GLP-1 and is a strong GLP-1 receptor agonist [21].
It is administered subcutaneously twice daily. A slow release
formulation for once-weekly administration (Exenatide LAR
[long-acting release]) is presently in clinical phase III studies
[22–24]. The long-acting human GLP-1 analogue liraglutide
(Victoza®, Novo Nordisk Pharmaceuticals) for once-daily
dosing has just been approved by the European Medicines
Agency (EMEA) [25–27]. Further compounds for once-daily
or once-weekly application are in development (taspoglutide,
Roche Pharmaceuticals [28]; AVE0010, Sanofi-Aventis
Pharmaceuticals [29]; albiglutide, GlaxoSmithKline Pharma-
ceuticals [30]).
Exenatide has a prolonged half-life in comparison to
native GLP-1 of approximately 3.5 h. After subcutaneous
injection sufficient plasma concentrations are reached for
4–6 hours [20, 31, 32]. Exenatide lowered the HbA1c by
0.8–1.1% in clinical studies [33–35]. The reduction of
HbA1c was constant over a time period of 3 years in one
study [16]. Comparative studies with insulin show that
effects of exenatide on glycaemic parameters are compara-
ble to the improvement seen with a newly started insulin
therapy [16, 20, 36–39].
Patients receiving exenatide showed a significant drop in
body weight by 1.5–3.0 kg after 30 weeks. The patients
who continued to use exenatide lost further weight (5.3 kg
after 3 years) [16, 40]. The comparative studies with insulin
showed a difference in weight development of 4–5k gi n
30 weeks between the insulin- and exenatide-treated groups
[36, 37, 39].
An improvement of beta cell function (measured with
the clinical surrogate parameters insulin secretion rate
HOMA B (homeostatic modelling assessment of beta cell
function) and the proinsulin:insulin ratio) was also observed
in the clinical studies. Furthermore, the first phase of
insulin secretion is restored after an intravenous glucose
bolus under treatment with exenatide [20, 40]. However, in
a 1-year study with exenatide and a consecutive wash-out
phase of 12 weeks, the improvements in the above-
mentioned beta cell function parameters were no longer
present after the end of the wash-out period [41].
Severe hypoglycaemic events were only observed in
exenatide-treated patients who had received combination
therapy with a sulphonylurea. In the comparative studies
comparing exenatide with insulin treatment, the rates of
hypoglycaemic episodes was similar in the patient group
that had sulphonylurea–exenatide combination therapy.
However, the incidence of nocturnal hypoglycaemic events
was lower in the exenatide-treated patients [20, 40].
The most frequent adverse events were fullness and
nausea. These were less pronounced when the exenatide
dose was titrated from a small dose to the full dose at the
beginning of treatment. Generally, nausea was mild to
moderate occurring in the first weeks of treatment and
ceasing with time. Nausea was the most common reason to
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with exenatide [16, 20, 40].
In approximately 40% of exenatide-treated patients,
anti-exenatide antibodies can be detected. Over a time
period of at least 3 years, these antibody titres did not
have any obvious effect on glycaemic control. Further-
more, the exenatide antibodies do not cross-react with
human GLP-1 [24].
Since exenatide has been approved, cases of acute
pancreatitis have been reported [42, 43]. The Food and
Drugs Administration of the United States (FDA) in
reaction then published a warning. In total, the incidence
of pancreatitis is very low and rather corresponds to the
elevated risk of pancreatitis in obese type 2 diabetic
patients. Type 2 diabetic patients have an elevated
pancreatitis risk due to a higher prevalence of gall stones,
hypertriglyceridaemia and other factors, and a recent meta-
analysis confirmed this [44].
Exenatide is predominantly eliminated by glomerular
filtration followed by proteolytic degradation [45]. Its use is
not recommended in patients with severe renal insufficien-
cy (creatinine clearance <30 ml/min). In patients with end-
stage renal disease on dialysis, exenatide (5 µg) has been
poorly tolerated because of gastrointestinal side effects [20,
40]. Just recently, the FDA published a warning after
having observed 78 cases of altered renal function under
exenatide therapy in the time period from 2005 to 2008.
These cases comprised 62 patients with acute renal failure
and 16 cases of renal insufficiency. Some cases occurred in
patients with pre-existing kidney disease or in patients with
one or more risk factors for developing kidney problems
[46]. These complications may have been associated with
nausea, vomiting and consecutive dehydration and worsen-
ing of kidney function. According to the warning by the
FDA, exenatide should not be used in patients with severe
renal impairment (creatinine clearance <30 ml/min) or end-
stage renal disease. Additionally, caution should be applied
when initiating or increasing doses of exenatide in patients
with moderate renal impairment (creatinine clearance 30–
50 ml/min). Patients should be carefully observed for the
development of kidney dysfunction under therapy.
There is one published paediatric study that investi-
gated the pharmacology and tolerability of a single dose
of exenatide in 13 adolescents (aged 10–16 years) with
type 2 diabetes and a baseline HbA1c of 8.2% on an
ongoing stable therapy with metformin, a sulphonylurea
or a combination of both. Pharmacokinetics and the
safety profile of exenatide were the primary endpoints.
The secondary endpoints comprised postprandial plasma
glucose, serum insulin as well as plasma glucagon
concentrations. The exenatide AUC (area under the
curve) expectedly appeared to be dose-dependent. How-
ever, exenatide was not quantifiable in all patients at the
lower 2.5- µg dose. Single doses of 2.5 µg and 5.0 µg of
exenatide were well tolerated and normalised postprandial
glucose and glucagon concentrations compared with placebo
(P<0.01). Insulin plasma concentration did not differ
significantly after exenatide and placebo. No hypoglycaemic
events were recorded during the study [47].
Liraglutide
Liraglutide is the first human GLP-1 analogue. It has two
modifications in the amino acid sequence of native GLP-1
and an attachment of a fatty acid side chain to the peptide.
It is injected subcutaneously once daily [26].
In animal studies with diabetic rodents, liraglutide has
been shown to increase beta cell mass. Liraglutide lowers
blood glucose, body weight and food intake in a broad
selection of animal models [48]. In clinical studies in type 2
diabetic patients involving approximately 4,200 patients
receiving the drug, it is efficacious and safe in the treatment
of type 2 diabetes across all stages of the natural course of
the disease [25, 49–54].
In a clinical study using liraglutide in monotherapy in
newly diagnosed type 2 diabetic patients it led to a
sustained and stable HbA1c reduction of 0.9–1.1% in a
dose of 1.2 or 1.8 mg once daily respectively, over a period
of up to 2 years [55, 56].
In other studies, the same doses of liraglutide effectively
lowered glycaemic parameters in various combinations
with oral antidiabetic drugs by approximately 1.0–1.5%.
Liraglutide treatment additionally led to a significant
weight loss comparable to that previously observed in
studies with exenatide [57, 58]. The weight loss was
accompanied by a more pronounced loss in visceral fat
than subcutaneous fat [57–59].
Furthermore, systolic blood pressure was lowered by 2–
6 mmHg in the liraglutide-treated patients. This effect was
independent of the weight loss, as the reduction of blood
pressure was already observed early on in therapy, when
weight loss had not yet occurred [54–56, 59].
The incidence of hypoglycaemic episodes was compa-
rable to placebo in all studies and study arms, where no
sulphonylurea was used in the combination with liraglutide
[57, 58]. Gastrointestinal symptoms were also common in
clinical studies with liraglutide, but nausea and vomiting
were less frequent and only reported for a shorter period at
the beginning of therapy compared with exenatide [60].
Antibody formation against liraglutide was only 8.6% in
the clinical studies [55–58]. In a study directly comparing
the clinical efficacy and safety of exenatide and liraglutide,
liraglutide had an advantage with regard to lowering the
glycaemic parameters HbA1c and fasting glucose and to
improving HOMA-B [60]. Liraglutide improves the first
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as the insulin response to a maximal stimulation with
arginine [61].
Data on the pharmacokinetic profile of liraglutide in
mild to moderate renal impairment show no alteration of
the profile [57, 58]. So far, no studies of paediatric patients
with type 2 diabetes and liraglutide therapy have been
published.
DPP-4 inhibitors: sitagliptin, vildagliptin
and saxagliptin
DPP-4 inhibitors are orally active and tolerated well. After
once- or twice-daily dosing they effectively inhibit DPP-4
and lead to a postprandial elevation of endogenous GLP-1
concentrations 2–3 times normal physiological levels [62,
63]. The presently available compounds are sitagliptin
(Januvia®, Merck Pharmaceuticals), vildagliptin (Galvus®,
Novartis Pharmaceuticals) and saxagliptin (Onglyza®,
AstraZeneca and Bristol-Myers Squibb Pharmaceuticals)
[64]. They are approved in combination with metformin, a
sulphonylurea or a glitazone or a combination of metformin
and a sulphonylurea. Sitagliptin is also approved for
monotherapy in the USA and in monotherapy for patients
with metformin contraindications or intolerance in Europe
[62]. There are fixed-dose combinations for both sitagliptin
and vildagliptin with metformin (sitagliptin plus metformin:
Janumet®, Merck Pharmaceuticals, vildaglitpin plus met-
formin: Eucreas®, Novartis Pharmaceuticals). Further DPP-
4 inhibitors are in clinical studies (alogliptin, Takeda
Pharmaceuticals [65]; linagliptin, Boehringer Ingelheim
Pharmaceuticals [66] and others) [64].
Sitagliptin is the first DPP-4 inhibitor to be approved. In
mono- as well as in combination therapy it lowers HbA1c
by 0.6–1.1% compared with placebo in a standard dose of
100 mg once daily [62, 67–69]. Likewise, it reduces fasting
plasma glucose and postprandial glucose significantly.
Sitagliptin was weight-neutral in all studies [62, 67–69].
As an add-on to an existing metformin therapy, it was able
to lower the HbA1c by 0.7%. In a primary combination
therapy with metformin, a constant and sustained reduction
of HbA1c and fasting plasma glucose was observed over a
time period of 2 years [70]. The incidence of hypoglycae-
mic episodes observed under sitagliptin was comparable to
that under placebo [69]. An improvement of the proinsulin:
insulin ratio as a surrogate parameter of beta cell function
was observed in clinical studies in sitagliptin-treated
patients [62, 67, 68, 70]. The most common side effects
of sitagliptin were unspecific, like headache, arthritis,
nasopharyngitis, respiratory or urinary tract infections and
rarely skin reactions [69]. Adverse events concerning
infections showed the largest difference compared with
placebo and were more frequent in the sitagliptin-treated
patients (sitagliptin 34.5%, placebo 32.9%; 95% confidence
interval −0.8 to 4.0) [71].
The elimination and excretion of sitagliptin is mainly
renal (75% of an oral dose is found in the urine as
unchanged drug); the elimination half-time is 12–14 h [72–
74]. Sitagliptin was also generally well tolerated and
effective in patients with impaired renal function. In this
study, a dose of 25 mg/day was chosen for patients with a
creatinine clearance of <30 ml/min or end-stage renal
disease, a dose of 50 mg/dl was given to patients with a
creatinine clearance between 30 and 50 ml/min [75, 76].
Vildaglitpin is the second available compound of the
DPP-4 inhibitors with approval in Europe and many other
countries. Its dosage is 50 mg twice daily. In clinical studies
testing vildaglitpin in monotherapy or combination therapy
with metformin, glimepiride, pioglitazone or insulin,
vildagliptin was able to decrease the HbA1c by approxi-
mately 0.5–1.0% [62, 67, 68]. As an add-on therapy to
metformin, it decreased the HbA1c by 0.65–1.1% [77].
Vildagliptin has a good safety and tolerability profile and
the most common adverse events are unspecific (flu-like
symptoms, headache, dizziness, rarely liver enzyme eleva-
tions during the initiation of therapy). The incidence of
hypoglycaemic episodes is also comparable to that of
placebo. Vildagliptin, like the other DPP-4 inhibitors, is
also weight-neutral. Study data with vildagliptin demon-
strated a positive influence on acute and medium-term
parameters for insulin secretion under vildagliptin treatment
[62, 68, 77]. In this respect, HOMA B improved as well as
the proinsulin:insulin ratio and the first phase of insulin
secretion after intravenous glucose [78]. Vildagliptin has
been tested in an elderly population, where it was shown to
be efficacious and safe [79].
Long-term studies investigating cardiovascular out-
comes and a possible positive influence on disease
progression of type 2 diabetes are being carried on with
DPP-4 inhibitors.
Saxagliptin was subjected to a large phase III study
program. A dose-range study showed a dose-dependent
reduction in HbA1c by 0.7–0.9% (baseline HbA1c
7.9%). Fasting plasma glucose was also lowered dose-
dependently [80]. In a study with drug-naïve patients,
saxagliptin lowered glycaemic parameters (HBA1c, fast-
ing plasma glucose and postprandial glucose) significantly
[81]. As an add-on medication to a therapy with either
metformin or a glitazone, saxagliptin also led to signifi-
cant metabolic improvements comparable to other DPP-4
inhibitors [64, 82–85]. Saxagliptin did not cause hypo-
glycaemia, was well-tolerated and was weight-neutral. A
meta-analysis of the clinical phase III studies showed
favourable data on the development of cardiovascular
events [86].
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incretin-based therapies
The incretin-based therapies offer a good alternative to the
established antidiabetic compounds due to their satisfying
antihyperglycaemic efficacy, their lack of risk of causing
hypoglycaemia and their positive effects on body weight
development. A further advantage is their positive effect on
the insulin response of the beta cells. At this time, however,
it is not yet clear, whether incretin-based therapies will lead
to a sustained and durable positive effect on beta cell
function and mass under clinical conditions in patients with
type 2 diabetes. Animal data suggest that the novel
compounds may lead to a retardation or halting of the
progression of type 2 diabetes.
The most patient-relevant and striking difference
between the incretin-based therapies is that GLP-1
receptor agonists are injectable agents, while DPP-4
inhibitors are effective orally (Table 1). Glycaemic
control seems to be improved more effectively by GLP-1
receptor agonists in comparison to DPP-4 inhibitors, but
the data of a study directly comparing the efficacy and
safety of liraglutide with sitagliptin are not yet available.
Also, only GLP-1 receptor agonists lead to a reduction in
body weight, whereas DPP-4 inhibitors are weight-neutral.
Nausea, the most common adverse event observed with
GLP-1 receptor agonist therapy is not observed in
treatment with DPP-4 inhibitors. So far, no characteristic
pattern of adverse events has been observed with the DPP-4
inhibitors. DPP-4 is also expressed on the plasma mem-
brane of T-lymphocytes, where it was first described as a
CD-26 receptor. However, no immunological alterations
have been observed with DPP-4 inhibitor therapy. Further-
more, DPP-4 has multiple substrates (all peptides with a
penultimate alanine or proline in the N-terminal position);
the physiological effect of DPP-4 inhibition on all
substrates has not been characterised in full detail as yet.
Further long-term studies should clarify the long-term
effects and safety of DPP-4 inhibitors.
Indications for incretin-based therapies and their
placement in treatment guidelines for type 2 diabetes
The DPP-4 inhibitors sitagliptin, vildagliptin and saxagliptin
are approved in many countries for an oral combination
therapy, when therapeutic goals are not reached with life-style
intervention and metformin monotherapy. The DPP-4 inhib-
itorsplayaroleinthisindicationintheGermanguidelinesand
a recommendation by the British National Institute for Health
and Clinical Excellence (NICE) for patients who should not
be treated with sulphonylureas in order to prevent hypogly-
caemia or further weight gain [87, 88]. A recent retrospective
study has shown that a higher incidence of hypoglycaemia is
associated with the development of symptoms of dementia
[89]. In this respect, hypoglycaemia avoidance as stated by
NICE, is an important therapeutic goal. It should be noted
that DPP-4 inhibitors lower the HbA1c by approximately
1.0% and that other treatment options (namely insulin)
should be considered, if the HbA1c is elevated by more than
1.0% or if metabolic control has decompensated. The
combination of metformin with DPP-4 inhibitors combined
two synergistic treatment principles, metformin acting on
insulin resistance and the DPP-4 inhibitor acting on the
glucose-dependent stimulation of insulin secretion and
inhibition of glucagon secretion (the same synergistic
principle of action applies to the combination of a glitazone
and a DPP-4 inhibitor). DPP-4 inhibitors are not inferior to
sulphonylureas in the combination with metformin regarding
glycaemic parameters [90]. Theoretically, DPP-4 inhibitors
Table 1 Differences between GLP-1 receptor agonists and DPP-4 inhibitors
Properties/action GLP-1 receptor agonists DPP-4 inhibitors
Application Subcutaneous Oral
“GLP-1” levels Pharmacological (>5x) Physiological (2–3x)
GLP-1 effects Interaction with receptors on target organs
(hormonal signal pathway)
Interaction with receptors on afferent nerves
(mixed neural/hormonal signal pathway)
Duration of “GLP-1” elevation Long, continuously On-off, postprandially
Other mediators No GIP, PACAP, others
Effect on gastric emptying Yes None/scanty
Appetite Reduced Barely influenced
Effect on body weight Weight loss Weight-neutral
Adverse events Nausea/fullness
Exenatide: antibodies (?)
(Elevation of liver enzymes with vildagliptin
in high doses?)
GIP gastric inhibitory polypeptide, PACAP pituitary adenylate cyclase activating polypeptide
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above-mentioned advantages are underlined by positive
outcomes in long-term studies concerning glycaemic and
other relevant endpoints as well as safety outcomes.
Therapy with a GLP-1 receptor agonist is a favourable
treatment option when oral therapy with metformin or a
combination therapy with metformin and a sulphonylurea
are insufficient and a simultaneous loss of body weight is
another therapeutic goal (e.g. obesity-associated complica-
tions and concomitant morbidity) or hypoglycaemia strictly
has to be avoided (see above). Therapy with a GLP-1
receptor agonist at this stage may be a favourable
alternative to initiating insulin treatment. If sulphonylureas
are used before initiation of GLP-1 receptor agonist
therapy, the sulphonylurea dose should be at least reduced
when adding the GLP-1 receptor agonist. In a large
proportion of patients, the sulphonylurea treatment can
even be stopped.
Incretin-based therapies may help to bring a larger
percentage of patients to their glycaemic goals. Fixed-
dose combinations of a DPP-4 inhibitor with metformin
may be a favourable alternative as the patient does not have
to take more tablets when intensifying oral antidiabetic
therapy with a DPP-4 inhibitor. Obese patients with weight
loss as another important therapeutic goal may profit from
therapy with a GLP-1 receptor agonist. The higher price of
the novel incretin-based therapies is outweighed in some
respects by the possibility of reducing the cost of blood
glucose monitoring that is not necessary for safety reasons
as long as the patient is not simultaneously treated with a
sulphonylurea.
Prevention of hypoglycaemic events and prevention of
further weight gain are important therapeutic goals consid-
ering the results of the ACCORD trial, which showed
increased mortality in patients with type 2 diabetes who
were allocated to the intensified treatment arm with an
HbA1c goal <6.0% and who were treated with multiple
combinations of the classical antidiabetic agents [91]. The
increased mortality rate in this group may be explained by
the higher gain in body weight and by the increased
incidence of hypoglycaemic episodes. On the other hand,
the 10-year follow up data of the UKPDS show that an
early and effective diabetes treatment not only lowers
microvascular complications, but also lowers macrovascu-
lar endpoints significantly [4]. With respect to these study
results, patients with a newly diagnosed type 2 diabetes
should have a treatment that enables them to reach
normoglycaemia in a safe way without the risk of
hypoglycaemia or weight gain.
A consensus statement published in 2008 by the American
Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD) separates the existing
antidiabetic compounds and treatment algorithms into well-
validated therapies (“tier 1”, comprising metformin, sulpho-
nylureas and insulin) and less well-validated therapies (“tier
2”, comprising pioglitazone and GLP-1 receptor agonists). In
this statement, the established substances are preferred
according to their published endpoint and safety data as well
as pharmaco-economic data. In the less well-validated
therapies, GLP-1 receptor agonists, however, have their place
as second therapeutic escalation after metformin failure in the
samelineasthewidelyusedtherapywithpioglitazone[92]. In
the German guidelines, DPP-4 inhibitors and GLP-1 receptor
agonists are placed in second line after metformin failure, if
the HbA1c does not exceed >7.5% [87].
Both incretin-based therapies may also play a role in the
earlier or later stages of type 2 diabetes, when effectiveness
is shown at these stages. Preliminary data show, that the
addition of a DPP-4 inhibitor to existing insulin therapy
further reduces HbA1c and may have a positive effect on
hypoglycaemic events [93, 94]. Combination studies with
insulin and GLP-1 receptor agonists are also being carried
out and should bring results soon. Furthermore, long-term
studies are underway, investigating the effect of incretin-
based therapies on disease progression. Results of these
studies are pending should be available by approximately
the middle of the next decade. If these studies show an
effect on disease progression, another argument in favour of
using incretin-based therapies early in the disease will be
supported by study data. Recently, animal and human
studies showed a positive influence of GLP-1 or GLP-1
receptor agonists on the cardiovascular system and on the
nervous system, describing neuroprotective effects [17, 95–
99]. These fields may also open novel indications for
incretin-based therapies [17]. However, long-term studies
on hard cardiovascular endpoints and safety finally have to
reveal important data in clarifying the efficacy, safety and
placement of incretin-based therapies in type 2 diabetes
therapy.
Incretin hormones, incretin-based therapy and renal
failure
GLP-1 has natriuretic actions that have been observed in
several studies. These actions are in parallel to a diminished
proton secretion. GLP-1 receptor activation most likely
influences the activity of the sodium-proton exchanger 3
(NHE3 = natrium-proton [H
+] exchanger 3) located in the
brush border membrane of the proximal tubular cells by
activation pathways involving cAMP (cyclic adenosine
mono-phosphate) and protein kinase A [100]. The GLP-1
receptor is expressed at the mRNA level and protein level
in proximal tubular kidney cells [101].
In an animal model of salt-sensitive obese db/db mice
GLP-1 receptor activation by exendin-4 administration
Pediatr Nephrol (2010) 25:1207–1217 1213inhibited the development of hypertension. After a high salt
load, urinary sodium excretion was delayed and hyperten-
sion was present in these animals. Exendin-4 was able to
attenuate the latter effect. Exendin-4 also prevented
angiotensin II-induced hypertension through the attenuation
of angiotensin II-induced high-salt sensitivity [102].
Changes in the secretion, in vivo degradation and
elimination of the incretin hormones GLP-1 and GIP in
patients with chronic renal insufficiency were characterised
in a small study involving 10 patients with moderate renal
failure (serum creatinine 2.18±0.86 mg/dl) receiving an
oral glucose tolerance test and GIP- and GLP-1 infusions
on separate occasions. After an oral glucose load, plasma
concentrations of intact GLP-1 and intact GIP are compa-
rable in patients with renal insufficiency and healthy
controls. The concentrations of the degradation products
GIP [3–42] and GLP-1 (9–36 amide) are significantly
higher in the patients than in the control subjects after oral
glucose or after an exogenous infusion of either GIP or
GLP-1. The insulin plasma concentrations were slightly
lower in the patients during all experiments, whereas
C-peptide levels tended to be increased. These data
underline the importance of the kidneys for the final
elimination of GIP and GLP-1. The initial DPP-4-
mediated degradation of both hormones is almost unaffected
byimpairmentofrenalfunction.DelayedeliminationofGLP-
1 and GIP in renal insufficiency may influence the pharma-
cokinetics and pharmacodynamics of DPP-4-resistant incretin
derivatives to be used for the treatment of patients with type 2
diabetes [103].
Incretin-based therapies and type 1 diabetes
Since GLP-1 has a positive effect on beta cell mass in
rodents as well as a beneficial effect on the survival of
isolated human islets in cell culture [6, 104, 105], it is
imaginable that incretin-based therapies may also be
advantageous in type 1 diabetes, possibly in combination
with immune therapy. First preclinical studies suggest that
theoretically such a combination therapy may be feasible in
the future [106]. Besides the positive effect on the beta
cells, GLP-1 may also influence glycaemic parameters in a
favourable way by slowing gastric emptying and affecting
glucagon secretion in type 1 diabetes [107]. A small
mechanistic study in type 1 diabetic individuals showed
that an intravenous GLP-1 infusion reduced fasting hyper-
glycemia in the morning, which was provoked by omitting
the basal insulin injection at night [108]. Preclinical and
animal studies should be undertaken to clarify the potential
influence of GLP-1 on beta cell mass in type 1 diabetes and
on possible alterations of the autoimmune process. Clinical
studies could then be implemented to investigate the
metabolic effects of incretin-based therapies in type 1
diabetes, provided there are no unwanted side effects on
immune function in the preclinical studies.
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